Evidence map›Paper›PMID 39102888›Full record

ArticleJournal of the National Cancer Institute. Monographs2024

Reporting tumor genomic test results to SEER registries via linkages.

Valentina I Petkov, Jung S Byun, Kevin C Ward, Nicola C Schussler, Natalie P Archer, Suzanne Bentler, Jennifer A Doherty, Eric B Durbin, Susan T Gershman, Iona Cheng and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The SEER Program's evolution: supporting clinically meaningful population-level research.Journal of the National Cancer Institute. Monographs · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Valentina I PetkovSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.ORCID 0009-0009-8297-5381
Jung S ByunSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Kevin C WardEmory University, Atlanta, GA, USA.
Nicola C SchusslerInformation Management Services, Inc, Calverton, MD, USA.
Natalie P ArcherCancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, TX, USA.
Suzanne BentlerIowa Cancer Registry, The University of Iowa, Iowa City, IA, USA.
Jennifer A DohertyHunstman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Eric B DurbinCancer Research Informatics Shared Resource Facility, Markey Cancer Center, Kentucky Cancer Registry, University of Kentucky, Lexington, KY, USA.
Susan T GershmanMassachusetts Cancer Registry, Boston, MA, USA.
Iona ChengDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4132-2893
Tabassum InsafNew York State Department of Health, New York State Cancer Registry, Albany, NY, USA.
Lou GonsalvesConnecticut Department of Public Health, Connecticut Tumor Registry, Hartford, CT, USA.
Brenda Y HernandezUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
Lori KochIllinois State Cancer Registry, Springfield, IL, USA.
Lihua LiuDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-2252-8407
Alain MonnereauPublic Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA.
Bozena M MorawskiCancer Data Registry of Idaho, Boise, ID, USA.
Stephen M SchwartzDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Antoinette StroupNew Jersey State Cancer Registry, Trenton, NJ, USA.
Charles WigginsDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Xiao-Cheng WuSchool of Medicine, Louisiana State University, New Orleans, LA, USA.ORCID 0000-0003-3663-5027
Sarah BondsSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Serban NegoitaSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-2477-0379
Lynne PenberthySurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.

Funding

CARDIOVASCULAR HEALTH STUDY (CHS) - TASK AREA C, STUDY CLOSEOUT75N92021D00006 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE · 2021 to 2024
$8.4M
SEER CORE INFRASTRUCTURE SUPPORT75N91021D00011 · NCI · TEXAS STATE DEPT OF HEALTH SERVICES · PI WILLIAMS, MELANIE · 2021 to 2025
$5.3M
SCIENTIFIC, OPERATIONS AND ADMINISTRATIVE RESOURCES (SOAR) TO THE NIH75N95021D00011 · NIDA · GAP SOLUTIONS, INC. · PI RUPPERT, STEVEN · 2025 to 2025
$775k
Developmental Neurotoxicity Human Neurosphere Assay Data Collection - task order 175N96021D00006 · NIEHS · LEIBNIZ-INSTITUT FUR UMWELTMEDIZINISCHE FORSCHUNG AN DER HEINRICH-HEINE UIVERSITY · PI FRITSCHE, ELLEN · 2021 to 2021
$370k
Cancer Data Registry of IdahoCDC HHS 1NU58DP006270CDC HHS 1NU58DP007140CDC HHS 6NU58DP006352-05-01chool of Public Health Louisiana State University Health New Orleans HHSN261201800007ICLC NIH HHS 75N90021D00009Department of Population and Public Health SciencesDivision of Public Health Sciences Fred Hutchinson Cancer Center HHSN2612018000041Emory UniversityHHS HHSN261201800002IIllinois State Cancer Registry 75N91021D00006Keck School of MedicineNCI NIH HHS 75N91021D00011NCI NIH HHS HHSN261201000041CNCI NIH HHS HHSN261201000041INCI NIH HHS HHSN261201300009CNCI NIH HHS HHSN261201300009INCI NIH HHS HHSN261201800001CNCI NIH HHS HHSN261201800002BNCI NIH HHS HHSN261201800002CNCI NIH HHS HHSN261201800003CNCI NIH HHS HHSN261201800004CNCI NIH HHS HHSN261201800005CNCI NIH HHS HHSN261201800006INCI NIH HHS HHSN261201800007CNCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800012CNCI NIH HHS HHSN261201800012INCI NIH HHS HHSN261201800013CNCI NIH HHS HHSN261201800013INCI NIH HHS HHSN261201800014CNCI NIH HHS HHSN261201800014INCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS HHSN261201800041CNew Jersey State Cancer Registry 75N91021D00009New York State Cancer Registry HHSN261201800005INHLBI NIH HHS 75N92021D00006NHLBI NIH HHS 75N92021D00009NHLBI NIH HHS 75N92021D00011NIDA NIH HHS 75N95021D00011NIEHS NIH HHS 75N96021D00006NIEHS NIH HHS 75N96021D00009NIH HHS 75N98021D00006NLM NIH HHS 75N97021D00006ORFDO NIH HHS 75N99021D00009Surveillance, Epidemiology and End Results HHSN261201800003ISurveillance, Epidemiology and End Results Program HHSN261201800012I_HHSN26100001Texas Cancer RegistryUniversity of California
6 · The paper itself

Abstract

backgroundPrecision medicine has become a mainstay of cancer care in recent years. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program has been an authoritative source of cancer statistics and data since 1973. However, tumor genomic information has not been adequately captured in the cancer surveillance data, which impedes population-based research on molecular subtypes. To address this, the SEER Program has developed and implemented a centralized process to link SEER registries' tumor cases with genomic test results that are provided by molecular laboratories to the registries.

methodsData linkages were carried out following operating procedures for centralized linkages established by the SEER Program. The linkages used Match*Pro, a probabilistic linkage software, and were facilitated by the registries' trusted third party (an honest broker). The SEER registries provide to NCI limited datasets that undergo preliminary evaluation prior to their release to the research community.

resultsRecently conducted genomic linkages included OncotypeDX Breast Recurrence Score, OncotypeDX Breast Ductal Carcinoma in Situ, OncotypeDX Genomic Prostate Score, Decipher Prostate Genomic Classifier, DecisionDX Uveal Melanoma, DecisionDX Preferentially Expressed Antigen in Melanoma, DecisionDX Melanoma, and germline tests results in Georgia and California SEER registries.

conclusionsThe linkages of cancer cases from SEER registries with genomic test results obtained from molecular laboratories offer an effective approach for data collection in cancer surveillance. By providing de-identified data to the research community, the NCI's SEER Program enables scientists to investigate numerous research inquiries.

Indexed as

GenomicsNeoplasmsRegistriesSEER ProgramFemaleGenetic TestingHumansMaleMedical Record LinkageNational Cancer Institute (U.S.)United States

Identifiers

PMID39102888
PMCPMC11300019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.